Table 3 Clinical characteristics according to the expression of mTOR
From: Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients
|  | mTOR negative,intermediate(n = 13) | mTOR strong(n = 17) | p value |
|---|---|---|---|
Age, years, median (range) | 64 (38-74) | 57 (38-70) | 0.714 |
Male sex | 5 (38.5) | 9 (52.9) | 0.484 |
Ever smoker | 4 (30.8) | 7 (41.2) | 0.708 |
FVC, % | 73.0 ± 15.2 | 74.8 ± 16.1 | 0.748 |
DLCO, % | 62.1 ± 20.3 | 64.1 ± 32.7 | 0.857 |
PaO2, mmHg | 99.8 ± 18.1 | 86.2 ± 11.6 | 0.023 |
BAL Neutrophil, % | 25.5 ± 24.5 | 21.3 ± 21.9 | 0.736 |
BAL Lymphocyte, % | 22.5 ± 12.9 | 14.2 ± 6.0 | 0.116 |
Radiologic honeycombing score | 1.7 ± 2.7 | 2.4 ± 2.6 | 0.351 |
Histologic fibrosis score | 10.1 ± 8.7 | 15.0 ± 8.1 | 0.034 |
Δ FVC, mL | 109 ± 375 | -151 ± 174 | 0.044 |
Δ DLCO, mL/mmHg/min | 0.72 ± 2.24 | -1.19 ± 1.36 | 0.023 |
Δ FVC, % | 6.7 ± 17.1 | - 4.4 ± 4.9 | 0.041 |
Δ DLCO, % | 5.2 ± 12.9 | - 5.2 ± 6.2 | 0.021 |
Survivors | 11 (84.6) | 13 (76.5) | 0.672 |
ZEB1 | 2.4 ± 2.4 | 3.7 ± 2.8 | 0.185 |
ROCK1 | 1.6 ± 1.9 | 4.4 ± 2.9 | 0.006 |